Paliperidone palmitate prolonged release suspension for injection (six monthly)
Indication
Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products
Grey
Brand:
Byannli
Nice TA:
Commissioning responsibility:
CCG (HRG included)
PbR excluded:
No
BNF chapter:
Central nervous system
Background
Recommendation
LSCMMG Recommendation:
Grey
Reason for decision:
Prioritised for review
Supporting documents: